Effect of dialysis membranes and ACE inhibitor on bradykinin levels during hemodialysis.
The effects of dialyzer membrane material and concurrent angiotensin converting enzyme (ACE) inhibitor on plasma bradykinin levels during hemodialysis were investigated. Six patients treated with an ACE inhibitor and 6 other patients not receiving an ACE inhibitor underwent three consecutive hemodialysis sessions with an AN-69 dialyzer and three sessions with a polysulfone dialyzer. The sequence of dialyzers (AN-69 followed by polysulfone or the reverse) was determined randomly. With the AN-69 membrane dialyzer, the plasma bradykinin level at the dialyzer outlet was significantly greater than that at the dialyzer inlet at 5 min but not at 10 min after initiation of dialysis, whereas no significant difference between inlet and outlet bradykinin concentrations was observed at either time with the polysulfone membrane dialyzer. The changes in plasma bradykinin level in patients with concurrent ACE inhibitor did not differ from those found in patients without ACE inhibitor. These results indicate that the AN-69 membrane stimulates bradykinin production at the initial stage of hemodialysis in patients with as well as without concurrent ACE inhibitor. Further study is necessary to clarify the exact role of ACE inhibitor in elevation of bradykinin levels during hemodialysis.
Akizawa
T
T
Fujigaoka Hospital, Showa University, Yokohama, Japan.
Kinugasa
E
E
Wakasa
M
M
Kohjiro
S
S
Koiwa
F
F
Koshikawa
S
S
D000707:Anaphylaxis / Q000209:etiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D001920:Bradykinin / Q000097:blood*; D006801:Humans; D007688:Kidneys, Artificial; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D001920:Bradykinin